Novo Nordisk股价因Wegovy在中国获批而上涨

Reported about 1 year ago

诺和诺德（Novo Nordisk）的股票价格飙升至创历史新高，因其热门的GLP-1减重药物Wegovy在中国获得批准。在中国的减重药市场中，这是一项重大的进展。该公司已经获得Wegovy在美国的批准，并正在扩大市场至中国。

You may also interested in these wikis

Trump's Trade War Shadows Oil Demand Forecasts

Jim Cramer Supports Wells Fargo Despite Analyst Downgrade

Waller Advocates for July Rate Cut Amid Fed Divisions

Cleveland-Cliffs Shares Surge 10.4% as Investors Anticipate Positive Q2 Earnings

JPMorgan Predicts Korean Stock Index Could Reach 5,000 in Two Years

Ramit Sethi Explains Why Home Equity Isn't What It's Cracked Up to Be

Exploring Luckin Coffee's First U.S. Locations in Manhattan

Decline in US Investor Support for Climate and Social Reforms

US Online Spending Hits $24.1 Billion as Summer Discounts Draw Shoppers

Hertz Global (HTZ) Soars 11.8% Following Price Target Upgrade

Back to all Wikis